This HTML5 document contains 45 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n12http://localhost/temp/predkladatel/
n13http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n17http://linked.opendata.cz/ontology/domain/vavai/
n14http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11120%2F14%3A43909177%21RIV15-MSM-11120___/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
n3http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n10http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11120%2F14%3A43909177%21RIV15-MSM-11120___
rdf:type
skos:Concept n17:Vysledek
dcterms:description
Based on the SYMPLICITY studies and CE (Conformite Europeenne) certification, renal denervation is currently applied as a novel treatment of resistant hypertension in Europe. However, information on the proportion of patients with resistant hypertension qualifying for renal denervation after a thorough work-up and treatment adjustment remains scarce. The aim of this study was to investigate the proportion of patients eligible for renal denervation and the reasons for noneligibility at 11 expert centers participating in the European Network COordinating Research on renal Denervation in treatment-resistant hypertension (ENCOReD). The analysis included 731 patients. Age averaged 61.6 years, office blood pressure at screening was 177/96 mm Hg, and the number of blood pressure-lowering drugs taken was 4.1. Specialists referred 75.6% of patients. The proportion of patients eligible for renal denervation according to the SYMPLICITY HTN-2 criteria and each center's criteria was 42.5% (95% confidence interval, 38.0%-47.0%) and 39.7% (36.2%-43.2%), respectively. The main reasons of noneligibility were normalization of blood pressure after treatment adjustment (46.9%), unsuitable renal arterial anatomy (17.0%), and previously undetected secondary causes of hypertension (11.1%). In conclusion, after careful screening and treatment adjustment at hypertension expert centers, only approximate to 40% of patients referred for renal denervation, mostly by specialists, were eligible for the procedure. The most frequent cause of ineligibility (approximately half of cases) was blood pressure normalization after treatment adjustment by a hypertension specialist. Our findings highlight that hypertension centers with a record in clinical experience and research should remain the gatekeepers before renal denervation is considered. Based on the SYMPLICITY studies and CE (Conformite Europeenne) certification, renal denervation is currently applied as a novel treatment of resistant hypertension in Europe. However, information on the proportion of patients with resistant hypertension qualifying for renal denervation after a thorough work-up and treatment adjustment remains scarce. The aim of this study was to investigate the proportion of patients eligible for renal denervation and the reasons for noneligibility at 11 expert centers participating in the European Network COordinating Research on renal Denervation in treatment-resistant hypertension (ENCOReD). The analysis included 731 patients. Age averaged 61.6 years, office blood pressure at screening was 177/96 mm Hg, and the number of blood pressure-lowering drugs taken was 4.1. Specialists referred 75.6% of patients. The proportion of patients eligible for renal denervation according to the SYMPLICITY HTN-2 criteria and each center's criteria was 42.5% (95% confidence interval, 38.0%-47.0%) and 39.7% (36.2%-43.2%), respectively. The main reasons of noneligibility were normalization of blood pressure after treatment adjustment (46.9%), unsuitable renal arterial anatomy (17.0%), and previously undetected secondary causes of hypertension (11.1%). In conclusion, after careful screening and treatment adjustment at hypertension expert centers, only approximate to 40% of patients referred for renal denervation, mostly by specialists, were eligible for the procedure. The most frequent cause of ineligibility (approximately half of cases) was blood pressure normalization after treatment adjustment by a hypertension specialist. Our findings highlight that hypertension centers with a record in clinical experience and research should remain the gatekeepers before renal denervation is considered.
dcterms:title
Eligibility for Renal Denervation Experience at 11 European Expert Centers Eligibility for Renal Denervation Experience at 11 European Expert Centers
skos:prefLabel
Eligibility for Renal Denervation Experience at 11 European Expert Centers Eligibility for Renal Denervation Experience at 11 European Expert Centers
skos:notation
RIV/00216208:11120/14:43909177!RIV15-MSM-11120___
n4:aktivita
n6:N n6:V
n4:aktivity
N, V
n4:cisloPeriodika
6
n4:dodaniDat
n10:2015
n4:domaciTvurceVysledku
n13:1304585 n13:9125035 n13:7283423 n13:2228734
n4:druhVysledku
n15:J
n4:duvernostUdaju
n11:S
n4:entitaPredkladatele
n14:predkladatel
n4:idSjednocenehoVysledku
14328
n4:idVysledku
RIV/00216208:11120/14:43909177
n4:jazykVysledku
n16:eng
n4:klicovaSlova
Sympathetic Denervation; Hypertension Resistant to Conventional Therapy; Antihypertensive Agents
n4:klicoveSlovo
n7:Sympathetic%20Denervation n7:Antihypertensive%20Agents n7:Hypertension%20Resistant%20to%20Conventional%20Therapy
n4:kodStatuVydavatele
US - Spojené státy americké
n4:kontrolniKodProRIV
[6FF8AD38A9B9]
n4:nazevZdroje
Hypertension
n4:obor
n18:FA
n4:pocetDomacichTvurcuVysledku
4
n4:pocetTvurcuVysledku
86
n4:rokUplatneniVysledku
n10:2014
n4:svazekPeriodika
63
n4:tvurceVysledku
Toušek, Petr Čurila, Karol Widimský, Petr Rosa, Ján
n4:wos
000335491900169
s:issn
0194-911X
s:numberOfPages
7
n3:doi
10.1161/HYPERTENSIONAHA.114.03194
n12:organizacniJednotka
11120